Log in

Relevant bibliographies by topics / MYCN / Dissertations / Theses

To see the other types of publications on this topic, follow the link: MYCN.

Dissertations / Theses on the topic 'MYCN'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 dissertations / theses for your research on the topic 'MYCN.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Vulcani-Freitas, Tânia Maria [UNIFESP]. "Perfil de expressão dos genes MYC, MYCN, TERT, ASPM e PRAME em Meduloblastoma." Universidade Federal de São Paulo (UNIFESP), 2010. http://repositorio.unifesp.br/handle/11600/9928.

Full text

Abstract:

Made available in DSpace on 2015-07-22T20:50:35Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-04-28<br>Meduloblastoma (MB) é o tumor maligno de sistema nervoso central (SNC) mais comum em criança, compreendendo 20% dos tumores primários de SNC e 40% dos tumores cerebelares da infância. Devido sua forte tendência metastática, o tratamento padrão pós-operatório inclui radio e quimioterapia, cujo impacto causa distúrbios endócrinos e de crescimento, e disfunção neurocognitiva a longo prazo. Frente a esses efeitos negativos, muitas pesquisas em meduloblastoma têm sido realizadas com in

APA, Harvard, Vancouver, ISO, and other styles

2

Östergren, Tiolina. "Identification of MYCN and SOX9 target genes and a study of drug treatment effects in medulloblastoma." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-262085.

Full text

Abstract:

Medulloblastoma (MB) is the most common malignant brain tumor affecting children. The transcription factors MYCN and SOX9 are associated with initiation, maintenance and recurrence of MB and are also connected to more aggressive tumors. In this study, a ChIP was performed to isolate DNA from genes that are transcriptionally regulated by these proteins. Identification of these target genes will reveal new potential drug targets and help us better understand the functions of MYCN and SOX9. The ChIP was not fully optimized during this project and the target genes were not sent for sequencing and

APA, Harvard, Vancouver, ISO, and other styles

3

George, Rani Elizabeth. "Gene co-amplification with MYCN in neuroblastoma." Thesis, University of Newcastle Upon Tyne, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.363879.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kenyon, Rebecca Margaret. "Analysis of the MYCN amplicon in neuroblastoma." Thesis, University of Newcastle Upon Tyne, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.321261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Stermann, Alexander. "MYCN-DNA-Vakzine zur Behandlung des Neuroblastoms." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2014. http://dx.doi.org/10.18452/16888.

Full text

Abstract:

Das Neuroblastom (NB) zählt zu den therapieresistentesten Tumoren des Kleinkindalters. Besonders NB-Patienten mit MYCN-Amplifikation sind mit einer schlechten Prognose konfrontiert. Neuere Studien legen nahe, dass eine spezifische aktive Immuntherapie gegen MYCN ein vielversprechender Ansatz zur Bekämpfung dieser malignen Erkrankung darstellen könnte. Zur Untersuchung dieser Hypothese wurde ein sogenanntes Minigen-Vakzin, welches für drei ausgewählte Epitope aus der MYCN-AS-Sequenz kodiert, generiert. Die Auswahl der Minigen-Epitope erfolgte mit dem MHC-Liganden-Vorhersageprogramm syfpeithi, w

APA, Harvard, Vancouver, ISO, and other styles

6

Duarte, Alexandra. "The interplay between MYCN and the DNA damage response : modulation of MYCN expression, its interactions with components of the DNA damage response and cellular responses to N-myc following genotoxic stress." Thesis, Imperial College London, 2012. http://hdl.handle.net/10044/1/9832.

Full text

Abstract:

The DNA damage response (DDR) forms a signaling cascade rapidly activated upon exposure to genotoxic stress. The DDR safeguards genomic integrity by halting cell cycle progression to allow repair of damaged DNA or by inducing cell death. Myc proteins are key regulators of cell proliferation that transcriptionally control the cell cycle machinery. Amplification of N-myc in neuroblastomas (MNA-NB) is associated with abrogation of the regulatory mechanisms that normally prevent aberrant cell proliferation and the interplay between N-myc and the DDR was here analysed. Initially, an association bet

APA, Harvard, Vancouver, ISO, and other styles

7

Ottaviani, Daniela. "In-Depth Characterization of Human Retinoblastoma Subtype 2 and Preclinical Models." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS001.

Full text

Abstract:

Le rétinoblastome, un cancer pédiatrique de la rétine en développement, est la tumeur intraoculaire la plus fréquente chez l’enfant et représente environ 4 % de tous les cancers infantiles. Bien qu'il s'agisse d'une maladie rare, l'hôpital Curie (centre de référence pour le rétinoblastome en France) accueille environ 50 à 60 nouveaux patients chaque année. Notre groupe a précédemment caractérisé deux sous-types de rétinoblastomes. Les tumeurs de type « cone-like » ou sous-type 1 sont plutôt différenciées et homogènes, présentent une surexpression des gènes liés aux cellules cônes (photorécepte

APA, Harvard, Vancouver, ISO, and other styles

8

Maeshima, Ruhina. "MYCN silencing as therapeutics for neuroblastoma using RNA interference." Thesis, University College London (University of London), 2018. http://discovery.ucl.ac.uk/10043849/.

Full text

Abstract:

Neuroblastoma (NB) is the most common solid tumour in childhood and accounts for 15% of childhood cancer deaths. It is known that high-risk NB is highly correlated with MYCN amplification. Overexpressed MYCN induces proliferation and cell growth and suppresses apoptosis and differentiation pathways in NB cells. Since RNA interference (RNAi) was first described, many research groups have investigated the application of RNAi with the use of short interfering RNA (siRNA). Our aim is to induce apoptosis and differentiation using RNAi as a novel therapeutic strategy for MYCN-amplified NB. Our hypot

APA, Harvard, Vancouver, ISO, and other styles

9

Schulze, Franziska. "Die Telomerlänge als Prognosefaktor in MYCN nicht-amplifizierten Neuroblastomen." Doctoral thesis, Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-200943.

Full text

Abstract:

Eines der charakteristischen Merkmale des Neuroblastoms stellt seine einzigartige biologische Heterogenität dar, die eine genaue Ausage des weiteren klinischen Verlaufes stark erschwert. Bestimmte prognostisch wirksame klinische, molekularbiologische und genetische Faktoren, wie zum Beispiel Alter bei Erstdiagnose, Tumorstadium, MYCN-Amplifikation und 1p Deletion, werden seit längerem zur Risikostratifizierung genutzt. Bereits in anderen Tumorerkrankungen konnte nun der Einfluß einer Telomerlängenveränderung auf das Gesamtüberleben von Patienten nachgewiesen werden. Telomere sichern die genomi

APA, Harvard, Vancouver, ISO, and other styles

10

Solari, Valeria. "MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cells." Thesis, University of Liverpool, 2014. http://livrepository.liverpool.ac.uk/2003528/.

Full text

Abstract:

Neuroblastoma (NBL) is the most common type of cancer diagnosed in the first year of life. It is a complex and heterogeneous disease that arises from the developing sympathetic nervous system. Despite numerous advances and the well-demonstrated role of MYCN in the pathogenesis of neuroblastoma, the mechanisms underlying its oncogenic function are not entirely understood and there is evidence that its function is, in part, dependent on the tumour microenvironment (TME). New and improved therapeutic targets are urgently required for this often lethal tumour. Heparan sulfate proteoglycans (HSPG)

APA, Harvard, Vancouver, ISO, and other styles

11

Dirks, Johannes [Verfasser], and Martin [Gutachter] Eilers. "Charakterisierung der Wechselwirkung zwischen N-Myc und Aurora-A im MYCN-amplifizierten Neuroblastom / Johannes Dirks ; Gutachter: Martin Eilers." Würzburg : Universität Würzburg, 2019. http://d-nb.info/1194836240/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Weber, Axel. "Identifizierung und praktische Anwendung molekularer Marker für eine Verbesserung der Prognosebeurteilung humaner Neuroblastome." Doctoral thesis, Universitätsbibliothek Leipzig, 2012. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-86808.

Full text

Abstract:

Die Abschätzung der Prognose für Patienten, insbesondere Kinder mit onkologischen Erkrankungen stellt eine große Herausforderung an die behandelnden Ärzte dar. Vor Beginn einer Therapie werden daher viele Informationen gesammelt, um einen Patienten möglichst gut in eine vordefinierte Risikogruppe stratifizieren und dementsprechend eine mehr oder weniger intensive Therapie anbieten zu können. Diese Einteilungen sind allerdings für keinen Malignomtyp mit 100%-iger Sicherheit möglich. Das ist die Ursache dafür, dass auch in niedrige Risikogruppen eingeteilte Patienten nicht auf die Therapie anspr

APA, Harvard, Vancouver, ISO, and other styles

13

Valli, Emanuele <1983&gt. "The role of MYCN-mediated transcriptional repression in neuronal physiopathology." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2012. http://amsdottorato.unibo.it/4809/1/Valli_Emanuele_tesi.pdf.

Full text

Abstract:

MYC is a transcription factor that can activate transcription of several targets by direct binding to their promoters at specific DNA sequences (E-box). Recent findings have also shown that it can exert its biological role by repressing transcription of other set of genes. C-MYC can mediate repression on its target genes through interaction with factors bound to promoter regions but not through direct recognition of typical E-Boxes. In this thesis, we investigated whether MYCN can also repress gene transcription and how this is mechanistically achieved. Moreover, expression of TRKA, P75NTR

APA, Harvard, Vancouver, ISO, and other styles

14

Valli, Emanuele <1983&gt. "The role of MYCN-mediated transcriptional repression in neuronal physiopathology." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2012. http://amsdottorato.unibo.it/4809/.

Full text

Abstract:

MYC is a transcription factor that can activate transcription of several targets by direct binding to their promoters at specific DNA sequences (E-box). Recent findings have also shown that it can exert its biological role by repressing transcription of other set of genes. C-MYC can mediate repression on its target genes through interaction with factors bound to promoter regions but not through direct recognition of typical E-Boxes. In this thesis, we investigated whether MYCN can also repress gene transcription and how this is mechanistically achieved. Moreover, expression of TRKA, P75NTR

APA, Harvard, Vancouver, ISO, and other styles

15

Ferrucci, Francesca <1986&gt. "Genetic and pharmacological modulation of the MYCN/MAX/MXD network." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2017. http://amsdottorato.unibo.it/8128/1/tesiPhD%20Ferrucci.pdf.

Full text

Abstract:

MYCN amplification is found in many types of infancy cancer of neuroendocrine origin, including neuroblastoma (NB). Since identification of correlation between MYCN status and poor prognosis, many efforts have been made to develop efficient MYCN targeting drugs. The rationale for choosing MYCN as a NB therapeutic target lies in its tightly controlled expression during embryonic development and its undetectable levels in adult. Moreover, it is found deregulated in highly malignant cancers. Kocak gene arrays highlights that low levels of MYCN antagonists MAX and MNT in presence of MYCN ampl

APA, Harvard, Vancouver, ISO, and other styles

16

Shipillis, Nicholas. "Investigation of system properties related to MYCN oncogene expression in neuroblastoma." Thesis, University of Manchester, 2012. https://www.research.manchester.ac.uk/portal/en/theses/investigation-of-system-properties-related-to-mycn-oncogene-expression-in-neuroblastoma(2e3ba06b-faec-449e-85be-730213e697b9).html.

Full text

Abstract:

Neuroblastoma (NB) is one the most common cancers in infancy and childhood, andpossession of amplified MYCN gene sequence (gene locus 2p24) is related toaggressive disease and poor prognosis, with a clear distinction established regardingthe survival of patients based on the gene copy-number of MYCN. However, theexpression of MYCN has been reported to vary between patients of even the sameNB subgroups and more importantly its significance in relation to NB prognosis isstill not clearly established with various reports presenting contradicting results.In this study, a bottom-up Systems Biology

APA, Harvard, Vancouver, ISO, and other styles

17

Park, Ji. "PRMT5 as a potential theraputic target for MYCN overexposing peadiatric cancers." Thesis, University of Bristol, 2017. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.743007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Weiher, Moritz Adrian. "INHIBITION MYCN- VERMITTELTER ZELLZYKLUSTRANSITION DURCH THYROID CANCER 1 (TC1) IM NEUROBLASTOM – ETABLIERUNG UND CHARAKTERISIERUNG DES TC1- ÜBEREXPRESSIONSPHÄNOTYPS IN HUMANEN SH-EP NEUROBLASTOMZELLEN UNTER DEM EINFLUSS VON MYCN." Doctoral thesis, Universitätsbibliothek Leipzig, 2015. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-189951.

Full text

Abstract:

Das Neuroblastom ist der dritthäufigste maligne Tumor im Kindesalter und ist für 15% der Todesfälle durch Krebs bei Kindern unter 14 Jahren verantwortlich. Viele molekularbiologische Vorgänge, die zu der heterogenen Prognose der Patienten beitragen, sind noch nicht verstanden. Als Hauptrisikomerkmal stellt sich die Amplifikation und erhöhte Expression von MYCN dar. In Vorarbeiten der Arbeitsgruppe von Prof. Christiansen zeigte MYCN Einfluss auf die Genregion von Thyroid Cancer 1 (TC1), das als neuer Marker für maligne Schilddrüsenkarzinome erkannt wurde. In der vorliegenden Arbeit wurden erste

APA, Harvard, Vancouver, ISO, and other styles

19

Samy, Mona. "Télomerase et destin des tumeurs neuroblastiques." Thesis, Paris 11, 2010. http://www.theses.fr/2011PA11T039/document.

Full text

Abstract:

La télomérase est une ribonucléoprotéine, constituée d’un composant ARN (hTR) qui sert dematrice à l’addition des séquences télomériques aux extrémités des chromosomes et d’un composantprotéique catalytique à activité de transcriptase inverse (hTERT). La réactivation de la télomérasedans 90% des cancers compense le raccourcissement des télomères, permettant ainsil’immortalisation et la survie des cellules tumorales. Ce rôle canonique de la télomérase estaujourd’hui bien documenté. Cependant des travaux récents suggèrent que la télomérase pourraitavoir d'autres fonctions indépendantes de son rô

APA, Harvard, Vancouver, ISO, and other styles

20

Chowath, Rashmi. "Role of Aurora kinase in Medulloblastoma development with correlation to MYCN activity." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-255237.

Full text

Abstract:

Brain tumors are abnormal tissue masses found, either malignant or benign in nature. Medulloblastoma is a brain tumor subtype found to arise in the hind region of the brain, which is highly malignant and has poor long term prospects in general. On the basis of the driving force behind the tumor, medulloblastoma is further subgrouped into 4 categories: WNT; SHH; Group 3 and Group 4 tumors. Group 3 tumors show a high expression of N-Myc protein which is seen in certain types of cancerous cells. The cell cycle is regulated at several checkpoints by cyclin/cdk inhibitors. The primary cilium is an

APA, Harvard, Vancouver, ISO, and other styles

21

Morton, Andrew Robert. "Delineating the Role of Enhancers in Extrachromosomal Oncogene Amplifications." Case Western Reserve University School of Graduate Studies / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=case158652329165979.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

DeWitt, John. "The Role of Ciliary Neurotrophic Factor and TRKB Signaling in Neuroblastoma." ScholarWorks @ UVM, 2013. http://scholarworks.uvm.edu/graddis/67.

Full text

Abstract:

Neuroblastoma is the most common pediatric cancer in infants, arising from the sympathoadrenal lineage of the neural crest. Despite recent advances in other pediatric cancers, long term survival in high risk cases of neuroblastoma remains below 40%. Therefore, to develop successful therapeutics targeting high risk tumors, further research into the mechanisms involved in high risk tumor formation is necessary. Prognosis in neuroblastoma is determined by a number of factors, including certain genetic and biological variables. The genetic variable correlated most with high risk disease is amplifi

APA, Harvard, Vancouver, ISO, and other styles

23

Nortmeyer, Maike Christine [Verfasser], and Thomas [Akademischer Betreuer] Höfer. "MYCN dependency of MYCN amplified neuroblastoma cell lines analyzed in relation to their interaction with BET proteins and in a novel orthotopic mouse model / Maike Christine Nortmeyer ; Betreuer: Thomas Höfer." Heidelberg : Universitätsbibliothek Heidelberg, 2019. http://d-nb.info/1192373022/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Nortmeyer, Maike [Verfasser], and Thomas [Akademischer Betreuer] Höfer. "MYCN dependency of MYCN amplified neuroblastoma cell lines analyzed in relation to their interaction with BET proteins and in a novel orthotopic mouse model / Maike Christine Nortmeyer ; Betreuer: Thomas Höfer." Heidelberg : Universitätsbibliothek Heidelberg, 2019. http://d-nb.info/1192373022/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Chen, Lindi. "An investigation of the relationship between p53 fuction, differentiation and MYCN in neuroblastoma." Thesis, University of Newcastle Upon Tyne, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.519448.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ryl, Tatsiana [Verfasser], and Thomas [Akademischer Betreuer] Höfer. "MYCN, proliferative heterogeneity and treatment response in neuroblastoma / Tatsiana Ryl ; Betreuer: Thomas Höfer." Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1180985125/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Scott, Deborah Karen. "Identification and characterisation of genes co-amplified with the MYCN oncogene in neuroblastoma." Thesis, University of Newcastle Upon Tyne, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268359.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Cantelli, Erika <1981&gt. "Preclinical neuroblastoma models for a pharmacological study of a new MYCN oncogene inhibitor." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/4068/1/Cantelli_Erika_tesi.pdf.

Full text

Abstract:

Background. Neuroblastoma is the most deadly solid tumor of childhood. In the 25% of cases it is associated with MYCN amplification (MA), resulting in the disregulation of several genes involved in cancer progression, chemotherapy resistance and poor prognosis causing the disregulation of several genes involved in cancer progression and chemotherapy resistance and resulting in a poor prognosis. Moreover, in this contest, therapy-related p53 mutations are frequently found in relapsed cases conferring an even stronger aggressiveness. For this reason, the actual therapy requires new antitumor mol

APA, Harvard, Vancouver, ISO, and other styles

29

Cantelli, Erika <1981&gt. "Preclinical neuroblastoma models for a pharmacological study of a new MYCN oncogene inhibitor." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/4068/.

Full text

Abstract:

Background. Neuroblastoma is the most deadly solid tumor of childhood. In the 25% of cases it is associated with MYCN amplification (MA), resulting in the disregulation of several genes involved in cancer progression, chemotherapy resistance and poor prognosis causing the disregulation of several genes involved in cancer progression and chemotherapy resistance and resulting in a poor prognosis. Moreover, in this contest, therapy-related p53 mutations are frequently found in relapsed cases conferring an even stronger aggressiveness. For this reason, the actual therapy requires new antitumor mol

APA, Harvard, Vancouver, ISO, and other styles

30

Nguyen, Tue Gia Women's &amp Children's Health Faculty of Medicine UNSW. "Combined transcription modulating agents to overcome MycN-mediated retinoid reistance in hish risk neuroblastoma." Publisher:University of New South Wales. Women's & Children's Health, 2007. http://handle.unsw.edu.au/1959.4/44285.

Full text

Abstract:

Neuroblastoma (NB) is the most common solid tumor of early infancy. Despite a significant improvement in the general survival rate for children with cancer, the prognosis of high-risk NB remains low, at about 30%, despite the use of intensive chemo-radiotherapy followed by differentiation therapy with retinoic acid (RA). Relapses in this category of NB are often due to the emergence of multi-drug and RA-resistant minimal residual cancer cells. The use of natural 13-cis RA, as a single chemo-preventive agent, has improved the survival rate to 50% for high-risk NB patients. However, the prevalen

APA, Harvard, Vancouver, ISO, and other styles

31

Stermann, Alexander [Verfasser], N. [Akademischer Betreuer] Lode, Lockau [Akademischer Betreuer], and Schramm [Akademischer Betreuer]. "MYCN-DNA-Vakzine zur Behandlung des Neuroblastoms / Alexander Stermann. Gutachter: N. Lode ; Lockau ; Schramm." Berlin : Humboldt Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2014. http://d-nb.info/1047145472/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ciaccio, Roberto <1990&gt. "Multi-omic analyses of the MYCN network unveil new potential vulnerabilities in childhood neuroblastoma." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2021. http://amsdottorato.unibo.it/9930/1/PhD%20thesis%20Ciaccio%20Roberto_2021.pdf.

Full text

Abstract:

Neuroblastoma is the first neurogenic-extracranial solid cancer occurring in infancy and childhood. The genetic aberration most commonly associated with a poor prognosis is MYCN gene’s amplification. We hypothesize that effective anti-MYC therapeutics can be developed by understanding the regulation and function of N-MYC in neuroblastoma. Since N-MYC is an intrinsically disordered protein, it is still challenging to target this transcription factor, however, the model is shifting significantly after discovering novel therapeutic targets that impact MYC-driven tumorigenesis. The following work

APA, Harvard, Vancouver, ISO, and other styles

33

Boulos, Nidal. "Influence of MYCN expression and chromosome 1p deletion on responses of neuroblastoma to chemotherapeutic drugs." Thesis, University of Newcastle Upon Tyne, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.401848.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Okiro, Patricia Opon. "Morphological classification of childhood medulloblastomas with β-catenin immunohistochemistry and mycn fluorescent in situ hybridization". Master's thesis, University of Cape Town, 2015. http://hdl.handle.net/11427/15733.

Full text

Abstract:

Medulloblastoma is the most frequently occurring childhood malignant brain tumour, affecting 1 of 5 children presenting with a brain tumour, between the ages of 0 and 9 years. The basic prognostic stratification that relies on clinical and histological findings alone has proven unsatisfactory as an outcome predictor. Distinct molecular genetic profiles have been described, with four molecular variants of medulloblastoma with specific demographic and prognostic features. These are the WNT subgroup, SHH subgroup, Group 3 and Group 4 tumours. The aim of this study was to describe the expression s

APA, Harvard, Vancouver, ISO, and other styles

35

Purgato, Stefania <1978&gt. "Inibizione selettiva del gene MYCN mediante PNA (acidi peptido nucleici) anti-gene nel rabdomiosarcoma umano." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2008. http://amsdottorato.unibo.it/690/1/Tesi_Purgato_Stefania.pdf.

Full text

Abstract:

MYCN oncogene amplification/expression is a feature of many childhood tumors, and some adult tumors, and it is associated with poor prognosis. While MYC expression is ubiquitary, MYCN has a restricted expression after birth and it is an ideal target for an effective therapy. PNAs belong to the latest class of nucleic acid-based therapeutics, and they can bind chromosomal DNA and block gene transcription (anti-gene activity). We have developed an anti-gene PNA that targets specifically the MYCN gene to block its transcription. We report for the first time MYCN targeted inhibition in Rhabd

APA, Harvard, Vancouver, ISO, and other styles

36

Purgato, Stefania <1978&gt. "Inibizione selettiva del gene MYCN mediante PNA (acidi peptido nucleici) anti-gene nel rabdomiosarcoma umano." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2008. http://amsdottorato.unibo.it/690/.

Full text

Abstract:

MYCN oncogene amplification/expression is a feature of many childhood tumors, and some adult tumors, and it is associated with poor prognosis. While MYC expression is ubiquitary, MYCN has a restricted expression after birth and it is an ideal target for an effective therapy. PNAs belong to the latest class of nucleic acid-based therapeutics, and they can bind chromosomal DNA and block gene transcription (anti-gene activity). We have developed an anti-gene PNA that targets specifically the MYCN gene to block its transcription. We report for the first time MYCN targeted inhibition in Rhabd

APA, Harvard, Vancouver, ISO, and other styles

37

Horvilleur, Emilie. "Interrelations entre les protéines de la famille p53 et MYCN dans la pathogenèse du neuroblastome." Paris 11, 2008. http://www.theses.fr/2008PA11T010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

LO, IACONO Valentina. "ONCOSUPPRESSOR ACTIVITY OF TRANSCRIPTIONAL REPRESSOR MBP-1 IN NEUROBLASTOMA LAN-5 CELLS." Doctoral thesis, Università degli Studi di Palermo, 2014. http://hdl.handle.net/10447/91258.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Flórez, Amaya Andrés Felipe [Verfasser], and Thomas [Akademischer Betreuer] Höfer. "MYCN modulates the restriction point and ferroptosis in Neuroblastoma / Andrés Felipe Flórez Amaya ; Betreuer: Thomas Höfer." Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1180739876/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Gamble, Laura Dawn. "MYCN and the p53-MDM2/MDMX-p14ARF network in neuroblastoma amd response to MDM2-p53 antagonists." Thesis, University of Newcastle upon Tyne, 2012. http://hdl.handle.net/10443/1350.

Full text

Abstract:

Background: MYCN-amplification is a major negative prognostic marker, occurring in 25-30% of neuroblastomas. MYCN plays contradictory roles in promoting cell growth and sensitizing cells to apoptosis, and we have recently shown that p53 is a direct transcriptional target of MYCN, and may be an important mechanism of MYCN-induced apoptosis. Although p53 mutations are rare in neuroblastoma at diagnosis, the p53/MDM2/p14ARF pathway is inactivated in 35% of cases through MDM2-amplification or p14ARF inactivation. Neuroblastoma is therefore an ideal target for p53 reactivation using MDM2-p53 antago

APA, Harvard, Vancouver, ISO, and other styles

41

Fix, Anne. "Caractérisation des amplifications génomiques et des mécanismes de surexpression de la protéine MYCN dans le neuroblastome." Paris 11, 2008. http://www.theses.fr/2008PA11T005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Flórez, Andrés [Verfasser], and Thomas [Akademischer Betreuer] Höfer. "MYCN modulates the restriction point and ferroptosis in Neuroblastoma / Andrés Felipe Flórez Amaya ; Betreuer: Thomas Höfer." Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1180739876/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Boisvilliers, Madryssa de. "Effets anti-tumoraux du VIP dans des cellules de neuroblastome." Thesis, Poitiers, 2015. http://www.theses.fr/2015POIT2283/document.

Full text

Abstract:

Le neuroblastome (NB) est un cancer pédiatrique dérivé de la crête neurale. Les NB à haut risque sont des tumeurs peu différenciées présentant une amplification de MYCN et les plus agressives possèdent en plus une mutation d'ALK. Pour améliorer le traitement de ces tumeurs, les nouvelles thérapies cherchent à induire la différenciation cellulaire, l'inhibition de MYCN et la réduction de la signalisation d'ALK. Les résultats obtenus indiquent que le VIP induit une neuritogenèse dans les cellules de NB à haut risque SK-N-DZ et Kelly, et réduit en plus l'expression de MYCN dans les cellules Kelly

APA, Harvard, Vancouver, ISO, and other styles

44

Masserot, Caroline. "WT1 et régulation de hTERT : cas du neuroblastome et de la leucémie aiguë promyélocytaire." Thesis, Paris 11, 2014. http://www.theses.fr/2014PA11T091.

Full text

Abstract:

La télomérase, enzyme qui permet le maintien de la longueur des télomères est activée dans la majorité des cellules cancéreuses. Du fait de son rôle dans l’immortalité cellulaire, elle a été proposée comme cible de nouvelles stratégies anticancéreuses; il est donc fondamental d’identifier les mécanismes de sa régulation. Des travaux récents du laboratoire ont démontré, en utilisant une lignée de leucémie aiguë promyélocytaire résistante à la différenciation par les rétinoïdes (NB4-LR1), que l’acide rétinoïque tout trans (ATRA) induit une répression transcriptionnelle de hTERT, sous-unité catal

APA, Harvard, Vancouver, ISO, and other styles

45

Röschert, Isabelle [Verfasser], Martin [Gutachter] Eilers, and Manfred [Gutachter] Gessler. "Aurora-A prevents transcription-replication conflicts in MYCN-amplified neuroblastoma / Isabelle Röschert ; Gutachter: Martin Eilers, Manfred Gessler." Würzburg : Universität Würzburg, 2021. http://d-nb.info/1239052804/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Weiher, Moritz Adrian [Verfasser], Holger [Akademischer Betreuer] Christiansen, Sven [Akademischer Betreuer] Starke, Ulrich H. [Gutachter] Thóme, and Gerhard [Gutachter] Behre. "Inhibition MYCN-vermittelter Zellzyklustransition durch Thyroid Cancer 1 (TC1) im Neuroblastom – Etablierung und Charakterisierung des TC1-Überexpressionsphänotyps in HUMANEN SH-EP Neuroblastomzellen unter dem Einfluss von MYCN / Moritz Adrian Weiher ; Gutachter: Ulrich H. Thóme, Gerhard Behre ; Holger Christiansen, Sven Starke." Leipzig : Universitätsbibliothek Leipzig, 2015. http://d-nb.info/1240241445/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Manoni, Eleonora. "Modellazione matematica delle dinamiche di rilevamento dell'espressione del gene N-MYC mediante un sensore biomolecolare sintetico." Master's thesis, Alma Mater Studiorum - Università di Bologna, 2016. http://amslaurea.unibo.it/10215/.

Full text

Abstract:

L'espressione del gene MYCN è un importante indicatore della severità del NBL. Poiché il numero di copie di MYCN è un indice grezzo della sua espressione quantificarle utilizzando tecniche come la “fluorescent in situ hybridization” (FISH) può servire a formulare una stima del livello di espressione MYCN [Shapiro 1993]. Tuttavia, l'espressione aberrante di MYCN nel NBL non è sempre associata all'amplificazione genica; pertanto la valutazione diretta del livello di espressione di questo gene sarebbe un miglior indicatore prognostico. Questa tesi è stata sviluppata nell'ambito di un pr

APA, Harvard, Vancouver, ISO, and other styles

48

Savov, Vasil. "The Role of SOX9 in Medulloblastoma." Doctoral thesis, Uppsala universitet, Institutionen för immunologi, genetik och patologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-274630.

Full text

Abstract:

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Overall survival is about 70% and in cases where current treatment fails, the disease recurs and most often is fatal. At the molecular level, MB can be divided into four defined subgroups: WNT, SHH, Group 3 and Group 4. Amplification of MYC family genes is common in MB and correlates with poor prognosis and tumor relapse. In this thesis we showed how MYCN initiates brain tumors when transduced in neural stem cells (NSCs). Prior to transduction, NSCs were isolated from different brain regions and at various time points. Wh

APA, Harvard, Vancouver, ISO, and other styles

49

Tong, Pak-ho, and 湯柏豪. "The cytotoxic effect of arsenic trioxide on human neuroblastoma cell lines and its relationship to MYCN gene status." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hdl.handle.net/10722/210315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Bell, Emma. "The role of MYCN in p53 activation and the downstream response to p53 after DNA damage in neuroblastoma." Thesis, University of Newcastle Upon Tyne, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.437980.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!